Objective To analyze late urinary toxicity after prostate cancer radiotherapy (RT): symptom description and identification of patient characteristics or treatment parameters allowing for the generation of nomograms. Methods Nine hundred and sixty-five patients underwent RT in seventeen French centers for localized prostate cancer. Median total dose was 70 Gy (range, 65-80 Gy), using different fractionations (2 or 2.5 Gy/day) and techniques. Late urinary toxicity and the corresponding symptoms (urinary frequency, incontinence, dysuria/ decreased stream, and hematuria) were prospectively assessed in half of the patients using the LENT-SOMA classification. Univariate and multivariate Cox regression models addressed patient or treatment-related predictors of late urinary toxicity (Cgrade 2). Nomograms were built up, and their performance was assessed.
Introduction
Radical prostatectomy (RP) and radiotherapy (RT) are cornerstones of localized prostate cancer treatment, leading to relatively similar results in terms of local control [1] . However, the side effects of both are different, mainly concerning the urinary adverse events. If the intensity of this toxicity after RT is relatively well-reported in the literature, the description of the symptoms corresponding to this toxicity is often limited. Moreover, the patient and/or treatment factors related to each of the side effects are not well known. Their identification is crucial. These factors could be used to generate urinary toxicity predictive tools (like nomograms), to guide the physician in deciding the treatment and to inform the patient, in this context of different therapeutic alternatives. To identify which radiation parameters increase toxicity is essential in understanding how to decrease toxicity, in particular due to new highly conformal radiotherapy techniques, such as intensitymodulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT).
These new techniques allow for an increase in the dose in the prostate, considering the strong dose-effect relationship for local control [2] , while limiting the dose in the bladder and the rectum. Their part in decreasing urinary toxicity has not, however, been clearly shown. If the relationship between dose-volume and toxicity has been consistently demonstrated for the rectum, it remains unclear for the bladder [3, 4] . Moreover, hypofractionated RT may be more efficient in eradicating prostate adenocarcinoma, but the impact of such modified fractionation on toxicity has not been well-established.
If nomograms have already been published to predict rectal bleeding and the risk of fecal incontinence [5, 6] , to our knowledge, no tools have as yet been developed to predict urinary toxicity.
We thus analyzed a large group of patients having received prostate cancer RT using different radiation techniques, total doses, and fractionations, to accurately quantify and describe late urinary toxicity, identify related risk factors and propose nomograms.
Materials and methods

Patient inclusion criteria
Records from 965 patients who received definitive radiotherapy for localized prostate adenocarcinoma were analyzed. Data were prospectively collected from 470 patients treated in 17 French institutions within two randomized studies: GETUG 06 (comparing 70-80 Gy) [7] and STIC-IGRT (testing IGRT) [8] , and retrospectively from 495 patients treated in two of them. All patients had a biopsyproven adenocarcinoma of the prostate. Pretreatment workup included a CT scan and a bone scan.
Patient and tumor characteristics
The following data were extracted from each randomized database: age, medical and surgical history (prior abdominal surgery, prior transurethral resection of prostate, anticoagulant treatment, diabetes, hypertension, and coronary insufficiency), and tumor characteristics (T stage, Gleason score, pretreatment PSA). Patients were staged by digital rectal examination according to the 1992 American Joint Committee on Cancer staging system [9] . Patients were classified into the three prognostic risk groups defined by D'Amico [1] . Patient and tumor characteristics are presented in Table 1 .
Treatment characteristics
The target volume comprised the prostate only in the low risk group (16 %), the prostate and the seminal vesicles in the other risk groups. The pelvic lymph nodes were not treated in the two randomized studies but may have been treated for high-risk patients of the two institutions (not treated in the randomized study) (9 %). The median total dose of the prostate was 70 Gy (ranging from 65 to 80 Gy), the seminal vesicles receiving 46 Gy, and the pelvic lymph nodes also 46 Gy, if treated. Dose per fraction was 2 Gy/ day, 5 fractions/week for 69 % of patients, or 2.5 Gy/day, 4 fractions/week for 31 % of patients.
The radiation technique was 3D conformational for the vast majority of patients (85 %) and 2D for 15 % of the patients, depending on the treatment period. IMRT and IGRT have been more recently used in patients receiving 80 Gy. Among the 41 % of the patients having received 80 Gy, the technique was a standard 3D conformal RT for 63 %, IMRT only for 18 %, and IMRT combined with IGRT in 19 %.
The 3D radiation technique was carried out following the French GETUG group recommendations, as previously reported [7] . Patients underwent simulation and treatment in the supine position. Target volume and organs at risk (bladder, rectum, and femoral heads) were delineated on CT slices. A bladder wall was generated with a thickness of 7 mm from the external manually delineated bladder contour according GETUG recommendations. The planning target volume (PTV) was calculated by adding a 10-mm margin in all directions except in the posterior where a 5-mm margin was considered. The dose-volume histogram had to respect the GETUG constraints [7] . The following bladder dosimetric data were analyzed: volume of the bladder wall, D max (maximal dose received in the bladder), D25 (minimal dose received in 25 % of the bladder wall), and D50 (minimal dose received in 50 % of the bladder wall).
Androgen deprivation therapy was given to 23 % of the patients, all presenting a high-risk cancer.
Details of treatment characteristics are presented in Table 1 .
Follow-up and toxicity grading
According to the protocol of surveillance, patients were evaluated every 3 months for a year, and every 6 months thereafter, late urinary toxicity was defined as events occurring more than 6 months after the beginning of RT. To determine the severity and incidence of main late urinary complaints, records were prospectively extracted from trial database or retrospectively from physicians' reports, at each follow-up visit. Urinary complaints were classified according to the LENTSOMA morbidity scoring system into four categories of symptoms: urinary frequency, dysuria, incontinence, and hematuria (Table 2) . Dysuria and decreased stream were considered as a single symptom. The analyses were performed for late urinary toxicity and for each of the symptoms, all being considered if Cgrade 2. Statistical analysis
The impact of the following parameters on late urinary toxicity (Cgrade 2) was tested at the 5-year mark:
• The data-recording modality (prospective vs retrospective collection) was verified as having no significant impact on the risk of toxicity.
The Kaplan-Meier method was used to calculate cumulative incidences of late urinary toxicity events (Cgrade 2). The differences between the survival curves were assessed using the log-rank test. Relationships between late urinary toxicity and patient, tumor or treatment parameters were first analyzed using Cox proportional hazard regression at univariate level. Multivariate analyses, including covariates statistically significant in univariate analysis, were carried out using the Cox proportional hazards model. The 5-year late urinary toxicity events were analyzed using logistic regression at univariate and multivariate levels. A p value B0.05 was considered statistically significant. Nomograms to predict 5-year late urinary toxicity and specific symptoms were built up according to the logistic model. To assess nomogram performance, a nonparametric fit of the predicted probability as regards the actual observed probability was made for each nomogram. The analyses were performed using the SPSS V18 (Chicago, IL) and R with the rms package. Nonparametric tests were used to compare the distribution of the parameters between different groups of treatment.
Results
The median follow-up was 61 months (range 6-206).
Late urinary toxicity: global quantification and symptom description Among the 965 patients, 183 events of late urinary toxicity grade 2 or greater were reported. Among them, only 14 % were toxicity grade 3 or 4. Ninety-two (50 %) corresponded to an increase in urinary frequency, 36 (20 %) to dysuria, and 48 (26 %) to hematuria. Only seven consisted of urinary incontinence grade 2 or greater. The 5-year and 10-year rates of grade 2 or higher urinary toxicity, urinary frequency, hematuria, dysuria, and urinary incontinence were 15 % (95 % CI 12-18 %) and 24 % (95 % CI 19-29 %), 10 % (95 % CI 8-12 %) and 15 % (95 % CI 11-19 %), 5 % (95 % CI 4-6 %) and 8 % (95 % CI 5-11 %), 3 % (95 % CI 2-4 %) and 8 % (95 % CI 4-12 %), and 1 % (95 % CI 0-2 %) and 2 % (95 % CI 0-4 %), respectively. Figure 1 presents cumulative incidence of global late urinary toxicity and the corresponding symptoms (Cgrade 2). The 5-and 10-year rates of grade 3 or higher global urinary toxicity were 3 % (95 % CI 2-4 %) and 7 % (95 % CI 5-9 %).
Nomograms to predict 5-year late toxicity
In multivariate analysis, the following preplanning parameters significantly positively associated with the 5-year risk of urinary toxicity: anticoagulant treatment (RR = 2.35), total dose (RR = 1.09), age (RR = 1.06), D25 (RR = 1.03), and D max (RR = 1.1) received by the bladder (Table 3) . Nomogram including pretreatment factors to predict 5-year risk of global late urinary toxicity (and its calibration plot) is presented in Fig. 2 .
The 5-year risk of urinary frequency was related to total dose (RR = 1.07) and diabetes (RR = 4). For dysuria, the total dose was the only significant factor (RR = 1.1) ( Table 3) . Figures 3 and 4 present nomograms to predict the 5-year risk of these urinary symptoms. The 5-year risk of hematuria was significantly increased by anticoagulant treatment (RR = 2.9).
Discussion
We showed that the incidence of late urinary toxicity symptoms continuously increases after RT, reaching a rate of 24 and 7 % at 10 years, for more than grade 2 and grade 3 urinary toxicity, respectively. These rates appear relatively similar to those previously observed after RT [7] . Urinary toxicity events may occur late after RT, later than those observed for late gastro-intestinal toxicity which generally reaches a plateau at 3 years after RT [10] . A longer follow-up is consequently required to properly estimate late urinary toxicity [10] . Comparing the risk of urinary toxicity after different treatments should therefore carefully consider the same follow-up. Late urinary toxicity symptoms are mainly characterized by urinary frequency (50 % of all events) and, to a lesser extent, by dysuria and hematuria. Incontinence is very rare (\2 % at 10 years).
We identified age, diabetes, and anticoagulant treatment as factors increasing the risk of late urinary toxicity by multivariate analysis. Diabetes has already been reported as a strong predictor of late urinary toxicity in prostate cancer radiotherapy [11] . The fact that anticoagulation or antiplatelet agents increase the risk of late urinary toxicity after prostate cancer radiotherapy has rarely been reported, even if this association concerns the risk of late rectal toxicity [12, 13] . However, anticoagulation has been already associated with gross hematuria in the whole population and could be an independent risk factor of urinary complaints whenever a radiation is performed. Age and diabetes have been previously associated with urinary side effects after radical prostatectomy, especially urinary incontinence [14, 15] . Thus, their implications in urinary toxicity after RT should not be underestimated in treatment decision.
We found a strong dose-effect relationship in urinary toxicity (global toxicity, urinary frequency, and dysuria). Most of the randomized studies comparing a ''standard'' dose (68 to 70 Gy) to a higher one (76 to 80 Gy) did not demonstrate such a significant increase in late urinary toxicity [16] [17] [18] [19] . However, in a large group of patients who received a dose escalation with 3D-CRT/IMRT, Zelefsky et al. [20] reported a significant increase in genitourinary (GU) toxicities after 10 years in patients who received higher doses. More recently, the GETUG 06 randomized trial reported such an increase, when escalating the dose from 70 to 80 Gy [7] . These differences can be explained by several reasons. The first one is the lack of follow-up. Indeed, the initial MDACC report that compared 78-70 Gy did not show a significant difference in late GI toxicity, while it was found with a longer follow-up [16] . Secondly, studies might be different in terms of their treatment scheme (dose, target volume, technique), patient characteristics, and grading scale. Finally, urinary toxicity might be more related to patient risk factors than dose parameters. Fig. 2 Five-year risk of global late urinary toxicity grade C2: nomogram and calibration plot. Calibration plot assessing the nomogram performance by a nonparametric fit of the predicted probability versus the actual observed probability
The lack of correlation between dose distribution (dosevolume histogram) and urinary toxicity may also be due to the large bladder volume variation occurring at the planning stage and at the different fractions, so that the planned dose distribution does not represent the actual delivered dose to the bladder.
A moderate hypofractionated schedule (2.5 Gy/fr) in our series did not increase late urinary toxicity. These results are concordant with contemporary studies [21] and emphasize the interest of hypofractionated schedule in prostate cancer radiotherapy. IMRT and IGRT aim at increasing local control by allowing dose escalation, while reducing toxicity by sparing normal surrounding tissues.
Compared to ''standard'' 3D conformal technique, IMRT clearly reduces the risk of long-term rectal toxicity and bowel dysfunction [20, 22, 23] . However, IMRT fails to decrease late urinary toxicity in most studies, as in the present one. Late urinary toxicity could even be partly due to prostatic urethra lesions [24] , and modern techniques such as IMRT combined with IGRT still do not allow for the preservation of this area. A recent non-randomized study of Zelefsky et al. [25] reported, however, that, with a median follow-up of 2.8 years and a high dose (86.4 Gy) delivered to the prostate by IMRT, patients treated with IGRT (using fiducials) experienced significantly less urinary toxicity than non-IGRT-treated patients. Based on this predictive factors, we propose the first nomograms to predict late urinary toxicity after radiation therapy. Indeed, many treatments now provide long-term survival and the decision of the patient concerning his own treatment is mainly based on expected side effects. These nomograms have been built up according to the pretreatment parameters, available before any CT simulation, in order to help physician and patient in the decision concerning the different prostate cancer treatments. Consequently, we believe that the corresponding nomograms concerning toxicity after radical prostatectomy should be proposed.
One limitation of our study is that both prospective and retrospective data (from 2 institutions) were used to assess our nomograms. However, the effect of data being retrospectively collected was not found to significantly impact on toxicity risk. Furthermore, a large number of patients were necessary to identify a maximum number of reliable toxicity predictors. Finally, nomogram performance has been validated within our series but should be also confirmed using external data.
Conclusions
We were able to identify several parameters increasing the risk of urinary toxicity after prostate cancer radiotherapy. The first nomograms to predict global late urinary toxicity and corresponding symptoms were generated, resulting in new tools for patient management and treatment decision, particularly between RT and surgery.
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